These studies stress OS but neglect to mention the local/distant morbidity associated with untreated prostate cancer. It's a shame the NYT article doesn't bring this up.
When the post-prostatectomy XRT studies first came out, the data for OS wasn't there but the evidence for decreased hormonal therapy usage and decreased metastatic disease was. An argument can be made for treating prostate cancer even if there is not an impact on survival. The morbidity (both physiologic and psychosocial) of bone metastases and that of androgen deprivation in men should not be trivialized, let alone be completely ignored.